

Medicinal product no longer authorised

**ANNEX I**

**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Nobivac Myxo-RHD lyophilisate and solvent for suspension for injection for rabbits

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of reconstituted vaccine contains:

### Active substance:

Live myxoma vectored RHD virus strain 009:  $\geq 10^{3.0}$  and  $\leq 10^{6.1}$  FFU\*

\*Focus Forming Units

### Excipients:

For the full list of excipients, see section 6.1.

## 3. PHARMACEUTICAL FORM

Lyophilisate and solvent for suspension for injection.

Lyophilisate: off-white or cream-coloured pellet.

Solvent: clear colourless solution.

Reconstituted product: off-pink or pink coloured suspension.

## 4. CLINICAL PARTICULARS

### 4.1 Target species

Rabbits.

### 4.2 Indications for use, specifying the target species

For active immunisation of rabbits from 5 weeks of age onwards to reduce mortality and clinical signs of myxomatosis and to prevent mortality due to rabbit haemorrhagic disease (RHD) caused by classical RHD virus strains.

Onset of immunity: 3 weeks.

Duration of immunity: 1 year.

### 4.3 Contraindications

None.

### 4.4 Special warnings for each target species

None.

### 4.5 Special precautions for use

#### Special precautions for use in animals

Vaccinate only healthy rabbits.

Rabbits that have been vaccinated previously with another myxomatosis vaccine, or that have experienced natural myxomatosis infection in the field, may not develop a proper immune response against rabbit haemorrhagic disease following vaccination.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

None.

#### **4.6 Adverse reactions (frequency and seriousness)**

A transient temperature increase of 1 - 2° C can commonly occur. A small, non-painful swelling (maximum 2 cm diameter) at the injection site is commonly observed within the first two weeks after vaccination. The swelling will resolve completely by 3 weeks after vaccination. In pet rabbits, in very rare cases, local reactions at the injection site such as necrosis, scabs, crusts or hair loss may occur. In very rare cases serious hypersensitivity reactions, which may be fatal, may occur after vaccination. In very rare cases the appearance of mild clinical signs of myxomatosis may occur within 3 weeks of vaccination. Recent or latent infection with field myxoma virus seems to play a role in this to a certain extent.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

#### **4.7 Use during pregnancy and lactation**

##### Pregnancy:

Studies involving the use of the vaccine during early pregnancy were inconclusive. Therefore vaccination is not recommended during the first 14 days of pregnancy.

##### Fertility:

No safety study on the reproductive performance has been conducted in male rabbits (bucks). Therefore, the vaccination of breeding bucks is not recommended.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

#### **4.9 Amounts to be administered and administration route**

Subcutaneous use.

After reconstitution, administer 1 dose of vaccine by subcutaneous injection to rabbits from 5 weeks of age onwards.

Revaccinate annually.

Ensure that the lyophilisate is completely reconstituted before use.

##### Single dose vial

Reconstitute a single dose vial of vaccine with 1 ml of Nobivac Myxo-RHD solvent and inject the total contents of the vial.

### Multi-dose vial

Solvent volume	Number of vials of freeze-dried vaccine to be added	Injection volume	Total number of rabbits that can be vaccinated
10 ml	1	0.2 ml	50
50 ml	5	0.2 ml	250

For proper reconstitution of the multi-dose vial, use the following procedure:

1. Add 1 - 2 ml of Nobivac Myxo-RHD solvent to the 50-dose vaccine vial(s) and ensure that the lyophilisate is fully dissolved.
2. Withdraw the reconstituted vaccine concentrate from the vial(s) and inject it back into the Nobivac Myxo-RHD solvent vial.
3. Ensure that the resulting vaccine suspension in the Nobivac Myxo-RHD solvent vial is properly mixed.
4. Use the vaccine suspension within 4 hours of reconstitution. Any reconstituted vaccine remaining at the end of this time should be discarded.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes) if necessary**

In addition to the adverse reactions observed after single dose vaccination, a mild swelling of the local lymph nodes may be observed within the first 3 days after overdose vaccination.

#### **4.11 Withdrawal period(s)**

Zero days.

### **5. IMMUNOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Immunologicals for leporidae, live viral vaccine, ATCvet code: QI08AD

To stimulate immunity against myxoma virus and rabbit haemorrhagic disease virus.

The vaccine strain is a myxoma virus expressing the capsid protein gene of rabbit haemorrhagic disease virus. As a consequence rabbits are immunised against both myxoma virus and rabbit haemorrhagic disease virus.

After infection with virulent myxoma virus some vaccinated animals may develop a few very small swellings, especially on hairless places of the body, which quickly form scabs. The scabs usually disappear within 2 weeks after the small swellings have been observed. These scabs are only observed in animals with active immunity and have no influence on the general health, appetite or behaviour of the rabbit.

### **6. PHARMACEUTICAL PARTICULARS**

#### **6.1 List of excipients**

Lyophilisate:  
Hydrolysed gelatine  
Pancreatic digest of casein  
Sorbitol  
Disodium phosphate dihydrate

Solvent:  
Disodium phosphate dihydrate  
Potassium dihydrogen phosphate  
Water for injections

## 6.2 Major Incompatibilities

Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the vaccine.

## 6.3 Shelf life

Shelf-life of the lyophilisate as packaged for sale: 2 years.

Shelf-life of the solvent as packaged for sale:

- 1 ml and 10 ml glass vials: 4 years.
- 50 ml PET vials: 2 years.

Shelf-life after reconstitution according to directions: 4 hours.

## 6.4 Special precautions for storage

### Lyophilisate:

Store in a refrigerator (2 °C – 8 °C).

Do not freeze.

Protect from light.

### Solvent (50 ml PET vial):

Store in a refrigerator (2 °C – 8 °C).

Do not freeze.

### Solvent (1 ml and 10 ml glass vial):

No special precautions for storage.

## 6.5 Nature and composition of immediate packaging

### Lyophilisate:

Glass vial of 1 or 50 doses closed with a halogenobutyl rubber stopper and aluminium cap.

### Solvent:

Glass vial of 1 ml or 10 ml or polyethylene terephthalate (PET) vial of 50 ml closed with a halogenobutyl rubber stopper and aluminium cap.

### Packaging:

- Plastic box with 5 x 1 dose vial of vaccine and 5 x 1 ml vial of solvent.
- Plastic box with 25 x 1 dose vial of vaccine and 25 x 1 ml vial of solvent.
- Cardboard box with 10 x 50 doses vial of vaccine + cardboard box with 10 x 10 ml vial of solvent.
- Cardboard box with 10 x 50 doses vial of vaccine + 2 x cardboard boxes each containing 1 x 50 ml vial of solvent.

Not all pack sizes may be marketed.

## 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products

Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.

## **7. MARKETING AUTHORISATION HOLDER**

Intervet International B.V.  
Wim de Körverstraat 35  
5831 AN Boxmeer  
The Netherlands

## **8. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/132/001-004

## **9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 07/09/2011  
Date of last renewal: 21/06/2016

## **10. DATE OF REVISION OF THE TEXT**

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu/>).

## **PROHIBITION OF SALE, SUPPLY AND/OR USE**

The manufacture, import, possession, sale, supply and/or use of Nobivac Myxo-RHD may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation. Any person intending to manufacture, import, possess, sell, supply and/or use Nobivac Myxo-RHD must consult the relevant Member State's competent authority on the current vaccination policies prior to the manufacture, import, possession, sale, supply and/or use.

**ANNEX II**

- A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. STATEMENT OF THE MRLs**

**A. MANUFACTURERS OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**

Name and address of the manufacturers of the biological active substance

Intervet International B.V., site De Bilt  
Ambachtstraat 2-6  
3732 CN De Bilt  
The Netherlands

Intervet International B.V., site Boxmeer  
Wim de Körverstraat 35  
5831 AN Boxmeer  
The Netherlands

Name and address of the manufacturer responsible for batch release

Intervet International B.V.  
Wim de Körverstraat 35  
5831 AN Boxmeer  
The Netherlands

**B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

Veterinary medicinal product subject to prescription.

**C. STATEMENT OF THE MRLs**

The active substance being a principle of biological origin intended to produce active immunity is not within the scope of Regulation (EC) No 470/2009.

The excipients listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or are considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.



Medicinal product no longer authorised

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

Medicinal product no longer authorised

**A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**BOX**

Plastic box with 5 x 1 dose of vaccine including 5 x 1 ml solvent vials (glass)  
Plastic box with 25 x 1 dose of vaccine including 25 x 1 ml solvent vials (glass)  
Cardboard box with 10 x 50 doses of vaccine

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Nobivac Myxo-RHD lyophilisate and solvent for suspension for injection for rabbits

**2. STATEMENT OF ACTIVE SUBSTANCES**

Live myxoma vectored RHD virus strain 009:  $\geq 10^{3.0}$  FFU/dose.

**3. PHARMACEUTICAL FORM**

Lyophilisate and solvent for suspension for injection

**4. PACKAGE SIZE**

5 x 1 dose of vaccine including solvent  
25 x 1 dose of vaccine including solvent  
10 x 50 doses of vaccine + 10 x 10 ml glass solvent vials  
10 x 50 doses of vaccine + 2 x 50 ml PET solvent vials

**5. TARGET SPECIES**

Rabbits

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Subcutaneous use.  
Read the package leaflet before use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period: Zero days.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

Once reconstituted use within 4 hours.

**11. SPECIAL STORAGE CONDITIONS**

Store in a refrigerator.

Do not freeze.

Protect from light.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Read the package leaflet before use.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only.

To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Intervet International B.V.

Wim de Körverstraat 35

NL - 5831 AN Bexmeer

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/132/001

EU/2/11/132/002

EU/2/11/132/003

EU/2/11/132/004

**17. MANUFACTURER'S BATCH NUMBER**

Lot {number}

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**BOX (SOLVENT ONLY)**

Cardboard box with 10 x 10 ml solvent vials (glass)

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Nobivac Myxo-RHD  
Solvent

**2. STATEMENT OF ACTIVE SUBSTANCES**

**3. PHARMACEUTICAL FORM**

**4. PACKAGE SIZE**

10 x 10 ml

**5. TARGET SPECIES**

Rabbits

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

**8. WITHDRAWAL PERIOD(S)**

**9. SPECIAL WARNING(S), IF NECESSARY**

**10. EXPIRY DATE**

EXP {month/year}

**11. SPECIAL STORAGE CONDITIONS**

No special storage conditions.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only.  
To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Intervet International B.V.  
Wim de Körverstraat 35  
NL - 5831 AN Boxmeer

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/132/003

**17. MANUFACTURER'S BATCH NUMBER**

Lot {number}

Medicinal product no longer authorised

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**BOX (SOLVENT ONLY)**

Cardboard box with 1 x 50 ml solvent vials (PET)

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Nobivac Myxo-RHD  
Solvent

**2. STATEMENT OF ACTIVE SUBSTANCES**

**3. PHARMACEUTICAL FORM**

**4. PACKAGE SIZE**

1 x 50 ml

**5. TARGET SPECIES**

Rabbits

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

**8. WITHDRAWAL PERIOD(S)**

**9. SPECIAL WARNING(S), IF NECESSARY**

**10. EXPIRY DATE**

EXP {month/year}

**11. SPECIAL STORAGE CONDITIONS**

Store in a refrigerator.  
Do not freeze.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, IF APPLICABLE**

For animal treatment only.  
To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Intervet International B.V.  
Wim de Körverstraat 35  
NL - 5831 AN Boxmeer

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/11/132/004

**17. MANUFACTURER'S BATCH NUMBER**

Lot {number}

Medicinal product no longer authorised



**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**  
**VACCINE VIAL LABEL**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Nobivac Myxo-RHD

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

Live myxoma vectored RHD virus.

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

1 dose  
50 doses

**4. ROUTE(S) OF ADMINISTRATION**

SC

**5. BATCH NUMBER**

Lot {number}

**6. EXPIRY DATE**

EXP {month/year}

**7. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**SOLVENT LABEL**

1 ml and 10 ml vial

**1. NAME OF THE SOLVENT**

Nobivac Myxo-RHD  
Solvent

**2. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

1 ml  
10 ml

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

EXP {month/year}

**5. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

Medicinal product no longer authorised

**PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**SOLVENT LABEL**

50 ml vial

**1. NAME OF THE SOLVENT**

Nobivac Myxo-RHD  
Solvent

**2. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

50 ml

**3. STORAGE CONDITIONS**

Store in a refrigerator.  
Do not freeze.

**4. BATCH NUMBER**

Lot {number}

**5. EXPIRY DATE**

EXP {month/year}

**6. THE WORDS "FOR ANIMAL TREATMENT ONLY"**

For animal treatment only.

Medicinal product no longer authorised

**B. PACKAGE LEAFLET**

## PACKAGE LEAFLET

Nobivac Myxo-RHD lyophilisate and solvent for suspension for injection for rabbits

### 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Intervet International B.V.  
Wim de Körverstraat 35  
5831 AN Boxmeer  
The Netherlands

### 2. NAME OF THE VETERINARY MEDICINAL PRODUCT

Nobivac Myxo-RHD lyophilisate and solvent for suspension for injection for rabbits

### 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each dose of reconstituted vaccine contains:

Live myxoma vectored RHD virus strain 009:  $\geq 10^{3.0}$  and  $\leq 10^{6.1}$  FFU\*

\*Focus Forming Units

Lyophilisate: off-white or cream-coloured pellet.

Solvent: clear colourless solution.

Reconstituted product: off-pink or pink coloured suspension.

### 4. INDICATION(S)

For active immunisation of rabbits to reduce mortality and clinical signs of myxomatosis and to prevent mortality due to rabbit haemorrhagic disease (RHD) caused by classical RHD virus strains.

Onset of immunity: 3 weeks

Duration of immunity: 1 year.

### 5. CONTRAINDICATIONS

None.

### 6. ADVERSE REACTIONS

A transient temperature increase of 1 - 2° C can commonly occur. A small, non-painful swelling (max. 2 cm diameter) at the injection site is commonly observed within the first two weeks after vaccination. The swelling will resolve completely by 3 weeks after vaccination. In pet rabbits, in very rare cases, local reactions at the injection site such as necrosis, scabs, crusts or hair loss may occur. In very rare cases serious hypersensitivity reactions, which may be fatal, may occur after vaccination. In very rare cases the appearance of mild clinical signs of myxomatosis may occur within 3 weeks of vaccination. Recent or latent infection with field myxoma virus seems to play a role in this to a certain extent.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reactions)
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

## 7. TARGET SPECIES

Rabbits.

## 8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

After reconstitution, administer 1 dose of vaccine by subcutaneous injection to rabbits from 5 weeks of age onwards.

Revaccinate annually.

## 9. ADVICE ON CORRECT ADMINISTRATION

Ensure that the lyophilisate is completely reconstituted before use.

### Single-dose vial

Reconstitute a single dose vial of vaccine with 1 ml of Nobivac Myxo-RHD solvent and inject the total contents of the vial.

### Multi-dose vial

Solvent Volume	Number of vials of freeze-dried vaccine to be added	Injection volume	Total number of rabbits that can be vaccinated
10 ml	1	0.2 ml	50
50 ml	5	0.2 ml	250

For proper reconstitution of the multidose vial, use the following procedure:

1. Add 1 - 2 ml of Nobivac Myxo-RHD solvent to the 50-dose vaccine vial(s) and ensure that the lyophilisate is fully dissolved.
2. Withdraw the reconstituted vaccine concentrate from the vial(s) and inject it back into the Nobivac Myxo-RHD solvent vial.
3. Ensure that the resulting vaccine suspension in the Nobivac Myxo-RHD solvent vial is properly mixed.
4. Use the vaccine suspension within 4 hours of reconstitution. Any reconstituted vaccine remaining at the end of this time should be discarded.

## 10. WITHDRAWAL PERIOD(S)

Zero days.

## 11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children.

Vaccine: Store in a refrigerator (2 °C – 8 °C). Do not freeze. Protect from light.

Solvent:

- Glass vial (1 ml or 10 ml): No special precautions for storage.
- PET vial (50 ml): Store in a refrigerator (2 °C – 8 °C). Do not freeze.

Do not use this veterinary medicinal product after the expiry date which is stated on the label.

Shelf-life after reconstitution according to directions: 4 hours

## 12. SPECIAL WARNING(S)

Special precautions for use in animals:

Vaccinate only healthy rabbits.

Rabbits that have been vaccinated previously with another myxomatosis vaccine, or that have experienced natural myxomatosis infection in the field, may not develop a proper immune response against rabbit haemorrhagic disease following vaccination.

Pregnancy:

Studies involving the use of the vaccine during early pregnancy were inconclusive, therefore vaccination is not recommended during the first 14 days of pregnancy.

Fertility:

No safety study on the reproductive performance has been conducted in male rabbits (bucks). Therefore, the vaccination of breeding bucks is not recommended.

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Overdose (symptoms, emergency procedures, antidotes):

In addition to the signs observed after single dose vaccination, a mild swelling of the local lymph nodes may be observed within the first 3 days after overdose vaccination.

Incompatibilities:

Do not mix with any other veterinary medicinal product, except the solvent supplied for use with the vaccine.

## 13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Dispose of waste material by boiling, incineration or immersion in an appropriate disinfectant approved for use by the competent authorities.

## 14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency <http://www.ema.europa.eu/>.

## 15. OTHER INFORMATION

To stimulate immunity against myxoma virus and rabbit haemorrhagic disease virus. The vaccine strain is a myxoma virus expressing the capsid protein gene of rabbit haemorrhagic disease virus. As a consequence rabbits are immunised against both myxoma virus and rabbit haemorrhagic disease virus.

The vector technology used to develop the vaccine strain allows the RHD virus component to be produced *in vitro* instead of using live rabbits for cultivation.

After infection with virulent myxoma virus some vaccinated animals may develop a few very small swellings, especially on hairless places of the body, which quickly form scabs. The scabs usually disappear within 2 weeks after the small swellings have been observed. These scabs are only observed in animals with active immunity and have no influence on the general health, appetite or behaviour of the rabbit.

- Plastic box with 5 x 1 dose vial of vaccine and 5 x 1 ml vial of solvent.
- Plastic box with 25 x 1 dose vial of vaccine and 25 x 1 ml vial of solvent.
- Cardboard box with 10 x 50 doses vial of vaccine + cardboard box with 10 x 10 ml vial of solvent.
- Cardboard box with 10 x 50 doses vial of vaccine + 2 x cardboard boxes each containing 1 x 50 ml vial of solvent.

Not all pack sizes may be marketed.

Medicinal product no longer authorised